HC Wainwright Reiterates Buy Rating for Altimmune (NASDAQ:ALT)

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 69.97% from the stock’s current price.

Several other research analysts have also issued reports on the stock. Stifel Nicolaus started coverage on shares of Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. UBS Group started coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Altimmune presently has an average rating of “Moderate Buy” and a consensus price target of $19.71.

Altimmune Stock Performance

Altimmune stock opened at $7.06 on Wednesday. Altimmune has a fifty-two week low of $5.28 and a fifty-two week high of $14.84. The stock has a market cap of $502.11 million, a price-to-earnings ratio of -4.55 and a beta of 0.22. The stock’s 50 day simple moving average is $7.89 and its two-hundred day simple moving average is $7.20.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the previous year, the company earned ($0.39) earnings per share. On average, analysts predict that Altimmune will post -1.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ALT. PFG Investments LLC bought a new stake in shares of Altimmune during the fourth quarter valued at approximately $96,000. SG Americas Securities LLC boosted its stake in Altimmune by 36.7% during the 4th quarter. SG Americas Securities LLC now owns 47,060 shares of the company’s stock valued at $339,000 after purchasing an additional 12,624 shares during the last quarter. Kraematon Investment Advisors Inc. bought a new stake in shares of Altimmune in the 4th quarter worth $222,000. Hennion & Walsh Asset Management Inc. raised its stake in shares of Altimmune by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 205,590 shares of the company’s stock worth $1,482,000 after purchasing an additional 31,482 shares during the last quarter. Finally, 180 Wealth Advisors LLC bought a new position in shares of Altimmune during the fourth quarter valued at $78,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.